Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system
Aizea Morales‐Kastresana, Shane A. Olwill(Pieris Pharmaceuticals (United States)), Alix Scholer‐Dahirel(Servier (France)), Janet K. Peper-Gabriel, Christian Barthels(QUIRIS Healthcare), Birgit Bossenmaier(Roche Pharma AG (Germany)), Eva-Maria Hansbauer(Pieris Pharmaceuticals (United States)), Thomas J. Jaquin(Pieris Pharmaceuticals (United States)), Lucia Pattarini(Servier (France)), Catherine Gallou, Véronique Blanc(Sanofi (France)), Christine Rothe, Rachida Bel Aiba(QUIRIS Healthcare), Marina Pavlidou(Pieris Pharmaceuticals (United States))
Cited by 1
Related Papers
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
|Clinical Cancer Research|2020|79
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
|PLoS ONE|2017|54
The phosphopantetheinyl transferase KirP activates the ACP and PCP domains of the kirromycin NRPS/PKS of Streptomyces collinus Tü 365
|FEMS Microbiology Letters|2011|24
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment
|Nature Communications|2025|13
Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains
|Frontiers in Pharmacology|2021|11